Biolase, Inc. BIOLQ
0.00
0.00
NaN
as of 23 Sep
- Market cap
- $2.3M
- P/E
- 0.0×
Follow BIOLQ
Growth Flags
show if company had growth for consecutive years
| Sep '24 | Jun '24 | Mar '24 | Dec '23 | Older periods | |
|---|---|---|---|---|---|
| 1,349.30% | (3,157.50%) | (1,229.27%) | (1,620.81%) |
+8 more TTM periods Free account |
|
| (100.09%) | (102.98%) | (100.28%) | (102.66%) | ||
ROIC |
(109.48%) | (171.31%) | (136.15%) | (118.79%) | |
Return on Tangible Assets |
424.86% | 750.88% | (454.12%) | (350.76%) | |
Average Days of Receivables |
27.99 | 38.34 | 42.51 | 40.71 | |
Free Cash Flow per Share |
(0.36) | (0.34) | (0.82) | (11.91) | |
Free Cash Flow |
(13.14) | (11.47) | (14.72) | (15.22) | |
Capital Expenditures |
0.29 | 0.07 | (0.34) | (1.13) | |
Piotroski F-Score |
3.00 | 3.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(91.93%) | (69.66%) | (69.53%) | (62.44%) | |
Accounts Receivable Turnover |
11.63 | 8.73 | 9.00 | 8.68 | |
Accounts Payable Turnover |
5.93 | 5.23 | 5.16 | 5.47 | |
Inventory Turnover |
2.55 | 2.55 | 2.21 | 2.38 | |
Average Days of Payables |
36.30 | 64.90 | 55.88 | 68.24 | |
Days of Inventory on Hand |
119.38 | 128.87 | 128.16 | 128.64 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
10.69% | 11.64% | 11.76% | 12.21% | |
Selling, General and Administrative Expense of Revenue |
53.11% | 57.20% | 57.66% | 58.29% | |
Share Based Compensation of Revenue |
2.46% | 3.42% | 3.95% | 3.42% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.41 | 0.32 | 0.38 | 0.37 | |
Depreciation/Fixed assets |
0.84 | 0.70 | 0.77 | 0.58 | |
Capex/Depreciation |
0.09 | 0.02 | (0.09) | (0.35) | |
Revenue per Share |
1.28 | 1.38 | 2.74 | 38.47 | |
Operating CF per Share |
(0.37) | (0.35) | (0.81) | (11.03) | |
Capex per Share |
0.01 | 0.00 | (0.02) | (0.88) | |
Capex to Sales |
(0.01) | 0.00 | 0.01 | 0.02 | |
Net Profit Margin |
(71.75%) | (78.50%) | (78.35%) | (76.52%) |
Columns are period end dates